Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP: 3.Outcomes from NATALEE and MonarchE

Now Viewing

EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following:

1. How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
   1. Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
   2. Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.
2. (Dr. O’Shaughnessy) What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
   1. Please include a discussion of the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib